


Creating MHC-Restricted Neoantigens with Covalent Inhibitors That Can Be Targeted by Immune Therapy



Takamitsu Hattori^{1,2}, Lorenzo Maso¹, Kiyomi Y. Araki¹, Akiko Koide^{1,3}, James Hayman¹, Padma Akkapeddi¹, Injin Bang¹, Benjamin G. Neel^{1,3}, and Shohei Koide^{1,2}



ABSTRACT

Intracellular oncoproteins can be inhibited with targeted therapy, but responses are not durable. Immune therapies can be curative, but most oncogene-driven tumors are unresponsive to these agents. Fragments of intracellular oncoproteins can act as neoantigens presented by the major histocompatibility complex (MHC), but recognizing minimal differences between oncoproteins and their normal counterparts is challenging. We have established a platform technology that exploits hapten-peptide conjugates generated by covalent inhibitors to create distinct neoantigens that selectively mark cancer cells. Using the FDA-approved covalent inhibitors sotorasib and osimertinib, we developed “HapImmune” antibodies that bind to drug-peptide conjugate/MHC complexes but not to the free drugs. A HapImmune-based bispecific T-cell engager selectively and potently kills sotorasib-resistant lung cancer cells upon sotorasib treatment. Notably, it is effective against KRAS^{G12C}-mutant cells with different HLA supertypes, HLA-A*02 and A*03/11, suggesting loosening of MHC restriction. Our strategy creates targetable neoantigens by design, unifying targeted and immune therapies.

SIGNIFICANCE: Targeted therapies against oncoproteins often have dramatic initial efficacy but lack durability. Immunotherapies can be curative, yet most tumors fail to respond. We developed a generalizable technology platform that exploits hapten-peptides generated by covalent inhibitors as neoantigens presented on MHC to enable engineered antibodies to selectively kill drug-resistant cancer cells.

See related commentary by Cox et al., p. 19.

INTRODUCTION

The past 20 years have witnessed a revolution in cancer therapeutics along two major fronts. First, “targeted therapies” (e.g., small-molecule signal transduction inhibitors, antibodies against receptor tyrosine kinases) have been developed against specific mutant oncogenes or components of their downstream signal transduction cascades (1, 2). Even KRAS, long viewed as “undruggable,” has now been targeted in tumors bearing the specific mutant allele KRAS^{G12C} (3–5). Targeted therapies can cause remarkable regressions, but unfortunately, some mutant cells are able to resist the initial drug onslaught via “adaptive resistance” (6–10) or as drug-tolerant persisters (11–16). Such cells can serve as reservoirs for the eventual development of stable resistance, which leads to disease recurrence and, ultimately, patient demise. In parallel, “immune therapies” emerged [e.g., immune-checkpoint blockade, adoptive T-cell transfer, chimeric antigen receptor (CAR) T cells, and CAR-natural killer (NK) cells]. These

modalities, unlike targeted therapies, can sometimes induce durable remissions (and likely cures), but most patients, including those with oncogene-driven tumors, fail to respond (17–25). Therefore, achieving durable responses and ultimately cures for metastatic cancers driven by intracellular oncogenes remains a major unmet medical need.

Conceivably, targeted therapies fail because they are unable to evoke a sustained antitumor immune response. Thus, a key question is how we can effectively combine the benefits of targeted therapies as debulking agents with the durability of immune therapies. In principle, aberrant intracellular oncoproteins could be recognized by the immune system. Specifically, mutant peptides derived from oncoproteins and presented on class I major histocompatibility complex (class I MHC, hereafter, MHC) molecules might be recognized by cytotoxic T cells with cognate T-cell receptors (TCR). That tumors are present, presumably due to immune escape, indicates that such T cells must be few in number, exhausted, senescent, or otherwise dysfunctional. Targeting mutant peptide/MHC complexes (hereafter p/MHC; e.g., KRAS mutants) with TCRs or antibodies is conceptually feasible and has been demonstrated in some cases (26, 27). Recognizing the typically minimal differences between the mutant and wild-type peptides in the context of the p/MHC complex makes this approach quite challenging (28).

To address these challenges, we developed a technology platform, “HapImmune,” that capitalizes on covalent targeted therapies to create drug-peptide conjugates as cancer neoantigens (Fig. 1A). The bulky chemical moiety of the conjugated inhibitor substantially alters the surface topography and chemistry with respect to unconjugated peptides. Thus, inhibitor-p/MHC should be a distinctly different and unique antigen, which could be more readily recognized by antibodies (or TCRs), leading to high selectivity. We utilized antibody-engineering technologies to develop human antibodies that recognize such neoantigens on MHC and

¹Laura and Isaac Perlmutter Cancer Center, New York University Langone Health, New York, New York. ²Department of Biochemistry and Molecular Pharmacology, New York University Grossman School of Medicine, New York, New York. ³Division of Hematology Oncology, Department of Medicine, New York University Grossman School of Medicine, New York, New York.

Note: T. Hattori and L. Maso contributed equally to this article.

Corrected online January 31, 2023.

Corresponding Authors: Shohei Koide, Smilow Research Center, Room 1105, 522 First Avenue, New York, NY 10016. Phone: 646-501-4601; E-mail: Shohei.Koide@nyulangone.org; and Benjamin G. Neel, Smilow Research Center, Suite 1201, 522 First Avenue, New York, NY 10016. Phone: 212-263-3019; E-mail: Benjamin.Neel@nyulangone.org

Cancer Discov 2023;13:132–45

doi: 10.1158/2159-8290.CD-22-1074

This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license.

©2022 The Authors; Published by the American Association for Cancer Research




Figure 1. The HapImmune concept. **A**, A covalent inhibitor enters the cell (step 1) and binds and forms a covalent bond with its target (step 2). As a part of natural protein turnover, the target-drug conjugate is degraded, and peptides with the conjugated drug are produced (steps 3 and 4). A drug-peptide conjugate is incorporated into a compatible MHC molecule (step 5). The drug-peptide/MHC complex translocates to the cell surface (step 6). A HapImmune antibody binds the complex (step 7) and recruits an immune effector cell, which initiates cell killing (step 8). Alternatively, the HapImmune antibody can serve as the recognition element for antibody conjugates or cellular therapies. **B**, Overview of antibody development strategy. The molecular model was based on Protein Data Bank ID 3RL1 (67). **C**, Peptides used in this study and their predicted HLA matches.

are minimally inhibited by the free inhibitor or inhibitor-p in the absence of MHC, a prerequisite for coadministration with the inhibitor. Such antibodies could kill tumor cells by engaging immune cells (e.g., T lymphocytes, NK cells, tumoricidal macrophages) or delivering toxic cargos (24, 29, 30). Importantly, the small-molecule drug need not act as an inhibitor of cancer cell growth or even as an inhibitor of the target protein, so long as it forms a stable covalent bond with the target protein and the inhibitor-p/MHC is presented on the surface of cancer cells. We present proof-of-concept data by developing highly specific human antibodies that specifically recognize complexes of inhibitor-peptide conjugates and their matched MHCs generated by two FDA-approved covalent drugs, sotorasib, which targets KRAS(G12C), and osimertinib, which targets activated EGFR. We also present initial data showing similar reagents can be generated for a third FDA-approved agent, ibrutinib, conjugated to a fragment of its target, BTK. Our concept enables the development and targeting of any drug-peptide conjugate capable of presentation on MHC and could substantially enhance the effectiveness of both targeted therapy and biologics against cancer.

RESULTS

Antigen Design for Inhibitor-Peptide Conjugates Originating from Sotorasib and KRAS(G12C)

We chose KRAS(G12C) as an initial target for testing the HapImmune concept. RAS mutations at codon 12 are among the most common oncogenic drivers, and these and other RAS-mutant proteins had long been viewed as challenging, if not “undruggable,” targets. Recent breakthroughs led to the development of multiple covalent inhibitors for KRAS(G12C), hereafter termed G12Cis. Sotorasib (AMG510) is the first FDA-approved G12Ci, and it evokes therapeutic responses and extends progression-free survival in a significant fraction of patients with non-small cell lung cancer whose tumors express the target oncoprotein (31). Unfortunately, as is the case for other targeted therapies, resistance to G12Ci develops quickly, and cures remain elusive (32–34).

We previously developed biologics (synthetic antibodies and monobodies) that directly target KRAS(G12C) and its covalent complex with ARS1620 (35, 36). Although these reagents are effective tools for mechanistic studies, their inability to enter cells made them ineffective as potential therapeutics.

Nevertheless, the relatively high abundance (~1 $\mu\text{mol/L}$) of KRAS(G12C) in cells (37), the effective target engagement by G12Ci, and the emerging mechanisms of sotorasib resistance all suggested that the sotorasib–KRAS(G12C) peptide conjugates might be amenable to the HapImmune approach.

Although no data explicitly demonstrate that sotorasib–peptide conjugates are presented on MHCs, much evidence suggested that this was likely. First, MHC presentation of RAS peptides that include residue 12 has been reported (27, 38). Cys12 in these p/MHC complexes should be located outside the anchor positions of the presented peptides that are crucial for MHC binding, suggesting that drug conjugation would minimally affect peptide presentation (Fig. 1B). Second, NetMHCpan (39) predicts that peptides containing Trp at the 12th position, mimicking the bulky side chain of sotorasib-conjugated Cys12, can be presented on HLA-A*03, HLA-A*11, and HLA-A*02, with the highest score for the 9-residue peptide corresponding to residues 8 to 16 (hereafter termed p_8 , where the subscript number indicates the position of the N-terminal residue of the peptide within the full-length, parental protein) on HLA-A*03 (Fig. 1B and C). For brevity, we will use abbreviations to refer to an inhibitor–peptide conjugate in complex with an MHC molecule: for example, soto- p_8 /A03 refers to the sotorasib- p_8 conjugate in complex with HLA-A*03.

We conjugated sotorasib to these peptides and produced their MHC complexes using a standard refolding procedure (40). Size-exclusion chromatography showed the formation of stable MHC complexes (Supplementary Fig. S1). As controls, we also prepared the corresponding complexes harboring the cognate wild-type peptides. Hereafter, peptides with the wild-type sequence are denoted as p^{WT} (see Fig. 1C for nomenclature of peptides used in this study).

Development of Antibodies Selective for Sotorasib–KRAS(G12C) Conjugates in Complex with MHC

We set out to develop antibodies that selectively recognize inhibitor–peptide conjugates in the context of MHCs. Using the soto- p_8 /A03 complex as a target and the p_8^{WT} /A03 complex as an off-target control for negative selection, we performed selections on a human synthetic antibody phage-display library and identified a clone, R001, that preferentially bound to soto- p_8 /A03 (Fig. 2A; Supplementary Fig. S2A). To facilitate the characterization and improvement of its properties, we transferred the phage-displayed Fab clone into a yeast display vector in the single-chain Fv (scFv) format. Consistent with its preliminary characterization as a phage-displayed Fab, R001 specifically bound to soto- p_8 /A03 with an apparent dissociation constant ($K_{D,\text{APP}}$) of 2.7 nmol/L and showed no binding to p_8^{WT} /A03 or p_7^{WT} /A03 (Supplementary Fig. S2A). This antibody was highly selective to soto- p_8 /A03. We detected significant but weak binding to soto- p_7 /A03, the p/MHC complex with a longer, 10mer peptide ($K_{D,\text{APP}} > 100$ nmol/L), but no binding to soto- p_7 /A11 and soto- p_8 /A11 complexes (Supplementary Fig. S2A). R001 also was highly selective to sotorasib, showing no cross-reactivity to two other G12Ci- p_8 /A03 complexes, ARS1620- p_8 /03 or MRTX849 (adagrasib)- p_8 /03 (Supplementary Fig. S2B).

To improve upon the affinity of R001 and to explore whether it is possible to expand its recognition spectrum to the related sotorasib-conjugated peptides on HLA-A*11 while maintaining selectivity for soto-p/MHC complexes, we performed rounds of affinity maturation (Fig. 2A; Supplementary Fig. S3). Following mutagenesis and library sorting of CDR residues, we developed clone R011, which showed increased affinity toward soto- p_7 /03 and weak but detectable binding to the soto- p_8 and soto- p_7 conjugates presented by HLA-A*11 (Fig. 2A; Supplementary Fig. S2A). We then performed deep mutational scanning (DMS; ref. 41) of the CDR-L3 and CDR-H3 residues of clone R011 to identify permissible substitutions (Fig. 2A; Supplementary Fig. S3). This step allowed us to define the sequence landscape of antibodies toward different soto-p/MHC antigens. Based on these data, we designed a tailored library that combined permissible residues in CDR-L3 and CDR-H3, and identified three clones, named R021, R022, and R023, that bound with low nanomolar affinity to all four targets: soto- p_8 /A03, soto- p_7 /A03, soto- p_8 /A11, and soto- p_7 /A11; Supplementary Fig. S2A). We chose clone R023 for further characterization and produced it in the Fab format for biophysical characterization. Biolayer interferometry (BLI) experiments using purified Fab confirmed its high affinity to all four soto-p/MHCs, with K_D values ranging from 110 pmol/L to 1.8 nmol/L (Fig. 2B), and lack of detectable binding to p^{WT} /MHCs (Fig. 2B, black traces). Intriguingly, BLI experiments also revealed that R023 bound, though with lower affinity, to sotorasib conjugated with a distinct peptide, p_5 , presented on a different HLA supertype, HLA-A*02 (Fig. 2C).

These antibodies bound only minimally to the free sotorasib-conjugated peptide in the absence of MHC or to free sotorasib. Binding to the free conjugate was observed only at very high concentrations (free soto-p $K_{D,\text{APP}} > 1$ $\mu\text{mol/L}$; Fig. 2D; Supplementary Fig. S2C). Furthermore, antibody binding to soto-p/MHCs was inhibited only marginally by free sotorasib [the half maximal inhibition concentration (IC_{50}) of 7–12 $\mu\text{mol/L}$, Fig. 2E and Supplementary Fig. S2D]. Remarkably, despite the ability of these antibodies to bind the sotorasib-conjugated peptides in a manner not restricted to a single HLA, their specificity toward the inhibitor–peptide conjugates in complex with MHCs, over free sotorasib, was maintained. Taken together, these data establish the feasibility of developing potent and selective antibodies to the complex of an inhibitor–peptide conjugate and its matched HLA that are minimally inhibited by the free inhibitor. These data also demonstrate the potential to expand the patient population that could be treated with this approach (see Discussion).

T-cell Engaging Bispecific Antibodies Selectively Kill Cells Presenting Drug–Peptide Conjugates as MHC Complexes

Direct detection of specific p/MHC complexes on the cell surface using standard immunochemical methods such as flow cytometry is extremely challenging because of their low copy number (38). Likewise, low copy numbers are expected for sotorasib–KRAS(G12C) conjugates presented by MHCs on the cell surface. Therefore, to detect these neoantigen complexes and maximize the efficacy of target cell killing by our antibodies, we utilized a T cell-engaging bispecific antibody platform. Specifically, we constructed a single-chain diabody




Figure 2. Development and binding properties of the R023 antibody. **A**, CDR sequences of R023 and its precursors and related clones. The middle images show the results of DMS of clone R011. The numbers indicate the total numbers of sequencing reads for each mutation, divided by the total number of reads for all mutations at the position, multiplied by 1,000. The crosses show the wild-type residue. **B**, BLI sensorgrams of the interaction between R023 Fab and the indicated MHC complexes. Biotinylated R023 Fab was immobilized, and binding of soluble p/MHC samples was measured. K_D values from global fitting are shown. **C**, BLI sensorgrams of the interaction between R023 Fab and the soto-p₅/A02 complex. **D**, Binding titration of scFv R023 displayed on the yeast cell surface to soto-p₇/A03 (blue) and the soto-p₇ conjugate in the absence of an MHC (open squares). arbit., arbitrary; MFI, median fluorescence intensity. **E**, Inhibition by free sotorasib of the interaction between soto-p₇/A03 (10 nmol/L) and scFv R023 displayed on the yeast cell surface. The binding signal intensity was normalized using the value without sotorasib (100%) and in the absence of soto-p₇/A03 (0%). IC_{50} values are reported \pm standard error. In **B** and **C**, each data point shows the mean ($n = 3$; technical replicates) of the median fluorescence intensity. Error bars represent the standard deviation.

(scDb; ref. 42) comprising a HapImmune antibody for recognizing the target cell and the UCHT1 clone as the component that engages CD3 ϵ on T lymphocytes (43), and used cell killing as a sensitive readout of p/MHC on the cell surface.

We used Raji cells harboring HLA-A*03 (Fig. 3A; Supplementary Fig. S4A) and pulsed with the soto-p₇ and soto-p₈ conjugates to ask whether the R023 scDb could have cytotoxic effects on cells displaying soto-p/A03 complexes. Raji cells express the transporter associated with antigen processing, which is required for the assembly of p/MHC complexes and their consequent transport to the cell surface (44). Consequently, MHC molecules on the Raji cell surface are already bound with endogenous peptides, and only a small fraction of HLA-A*03 on the surface of these cells can be loaded with exogenously added peptide–drug conjugates. When cocultured with T cells, the R023 scDb showed potent cytotoxic effects on cells pulsed with soto-p₇ or soto-p₈ ($EC_{50} = 2.8$ pmol/L and 5.2 pmol/L, respectively) but not with the p₇^{WT} or p₈^{WT} peptides, indicating selective killing (Fig. 3B). As predicted by our binding studies (Fig. 2B; Supplementary Fig. S2A), the cell killing efficacy of the R023 scDb was substantially higher than that

of the original R001 clone in the scDb format, particularly for cells pulsed with soto-p₇. Importantly, the R023 scDb showed no cytotoxic effect on sotorasib-treated, unpulsed Raji cells, which do not express KRAS(G12C) (Fig. 3C), indicating that the killing depends on the presence of KRAS(G12C) peptides. Notably, the R023 scDb also killed OCI-AML3 cells (expressing HLA-A*02) pulsed with soto-p₅ but not cells pulsed with p₅^{WT}, although the efficacy was lower than Raji cells pulsed with soto-p₇ or soto-p₈ (Fig. 3D). This result is consistent with the weaker affinity of R023 for the soto-p₅/A02 complex than for soto-p₇/A03 (Fig. 2B and C). In concert, these data show that the R023 scDb can induce potent, highly selective killing of cells presenting sotorasib–KRAS(G12C) peptide conjugates bound to MHC complexes on the cell surface. They also provide further evidence that the range of actionable MHCs can be extended via the HapImmune approach.

Sotorasib-Treated Tumor Cells Can Be Killed Selectively by HapImmune Antibodies

We next asked whether the R023 scDb can target sotorasib-treated KRAS(G12C)-harboring tumor cells that are




Figure 3. Cytotoxic effects of the R023 scDb on cells pulsed with a sotorasib-KRAS(G12C) conjugate. **A**, Schematic representation of the assay. Cells are pulsed with a conjugate or a negative control peptide, and then cocultured with T cells in the presence of scDb. **B**, Cytotoxic effects of scDbs on Raji cells pulsed with soto-p₇, soto-p₈, p₇^{WT}, or p₈^{WT}. **C**, Cytotoxic effects of the R001 and R023 scDbs on sotorasib-treated Raji cells, which do not possess KRAS(G12C). **D**, Cytotoxic effects of R023 on OCI-AML3 cells pulsed with soto-p₅ and p₅^{WT}. Data are from triplicate measurements, and calculated EC₅₀ values are shown. A3-2 is a positive control (pos. ctrl.) antibody that binds to HLA-A3 irrespective of the bound peptide. Data shown are representative of ≥2 equivalent measurements.

resistant to the inhibitor. The NCI-H358 cell line commonly used for studies of sotorasib and other G12Cis is highly sensitive to these agents and therefore not suitable for evaluating our approach. Instead, we identified a sotorasib-insensitive cell line, NCI-H2122 (hereafter H2122), that expresses KRAS(G12C) and HLA-A*03 (Supplementary Fig. S4B). H2122 is resistant to sotorasib at up to ~10 μmol/L in two-dimensional culture (Fig. 4A), a therapeutically relevant concentration range even though sotorasib at concentrations as low as 0.1 μmol/L fully engages KRAS(G12C) in these cells (Fig. 4B). By contrast, nearly all of the H358 cells were killed with 0.1 μmol/L sotorasib (Fig. 4A). Therefore, we chose to assess HapImmune scDb-induced killing in H2122 cells exposed to 0.1 to 1.0 μmol/L sotorasib. The sotorasib concentration in plasma remains higher than 0.1 μmol/L after a single administration of the standard 960 mg dose for nearly the entire 24-hour dosing interval (5). To specifically measure target cell death in the presence of T cells (some of which also die), we generated a variant of H2122 cells, H2122-NLuc, with intracellular expression of NanoLuc. Luciferase released into the media by dying cells can then be quantified, providing an accurate assessment of cancer cell death (45). In this manner, we avoid artifacts caused by cell death during detachment, which would be required for flow cytometry-based analysis.

We cultured H2122-NLuc cells in the presence of sotorasib for a week to allow adequate time for the processes of sotorasib engagement with KRAS(G12C), degradation of the sotorasib-KRAS(G12C) conjugate, and loading of the conjugates on HLA to reach a steady state (Fig. 1A). We chose this incubation period in order to account for the

slow turnover of KRAS ($t_{1/2} \geq 24$ h), which might limit the presentation of sotorasib-peptide conjugates by MHCs. Remarkably, coculture of sotorasib-pretreated H2122-NLuc cells with T cells in the presence of sotorasib and the R023 scDb resulted in efficient cell killing (Fig. 4C; Supplementary Fig. S5A). Although we predict that the copy number of soto-p/A03 on the cell surface is low, cell killing by the sotorasib/scDb combination was comparable with that evoked by a positive control scDb made with an antibody targeting all cell surface-expressed HLA-A*03, irrespective of its bound peptides, clone A3-2 (Fig. 4C; Supplementary Fig. S6). The EC₅₀ of the R023 scDb on sotorasib-treated H2122-NLuc was 29 pmol/L (Fig. 4D), whereas it showed no killing of vehicle-treated H2122. Cell killing was dependent on sotorasib concentration as expected (Fig. 4E). These results support the notion that selective targeting of inhibitor-p/MHC complexes could lead to a new immunotherapeutic approach.

We performed a series of rigorous control experiments to validate the proposed mechanism of tumor cell killing. Deletion of the *HLA-A3* allele in H2122-NLuc by means of CRISPR/Cas9 technology (Supplementary Fig. S4B) rendered these cells resistant to killing by the sotorasib/R023 scDb combination (Fig. 4F; Supplementary Fig. S5B). Likewise, the R023 scDb had no cytotoxic effects on cells harboring wild-type KRAS with either matched or mismatched HLAs (Fig. 4F; Supplementary Fig. S5B). Hence, killing of H2122 cells by the R023 scDb depends on the presence of the covalent targeted therapy drug, its target, and an appropriately matched HLA, providing strong support for the HapImmune concept (Fig. 1A).




Figure 4. Cytotoxic effect of the R023 scDb on sotorasib-treated tumor cells. **A**, Dose-response curves of the viability of H358 and H2122 cells following exposure to sotorasib for 72 hours. **B**, Analysis of sotorasib conjugation to KRAS(G12C) in H2122 cells by Western blot. H2122 cells were incubated with 100 nmol/L sotorasib for 24 hours. The arrow indicates KRAS(G12C) conjugated to sotorasib. Note that the anti-pan-RAS antibody detects KRAS, HRAS, and NRAS, so a complete shift of the original band is not expected. **C**, Cytotoxic effects of the indicated scDbs on H2122-Nluc cells treated with 1 $\mu\text{mol/L}$ sotorasib. The scDb concentration was 10 nmol/L except for the A3-2 scDb (1 nmol/L). pos. ctrl., positive control; RLU, relative light units. **D**, Cell killing titration curve of the R023 scDb on H2122-Nluc cells treated with 1 $\mu\text{mol/L}$ sotorasib. **E**, Dependence of cell killing on sotorasib concentration with the indicated scDbs at 1 nmol/L. **F**, HLA dependence of cell killing by R023 scDb. The normalized luminescence intensity (see Supplementary Fig. S5A for the procedure) is shown for cell lines treated with 0.3 $\mu\text{mol/L}$ sotorasib and cocultured with T cells in the presence of 1 nmol/L scDb and 0.3 $\mu\text{mol/L}$ sotorasib. KRAS mutation state and HLA alleles for the cell lines are shown. KO, knockout; WT, wild-type. **G** and **H**, Cytotoxic effects of the R023 scDb (1 nmol/L) on H2030-Nluc (**G**) and SW1573-Nluc (**H**) cells treated with sotorasib. Data shown are from technical quadruplicate measurements, representative of ≥ 2 equivalent measurements. Data represent mean \pm SD; one-way ANOVA with Tukey multiple comparison test; *, $P < 0.05$; ***, $P < 0.001$; ns, not significant. See Supplementary Fig. S5 for raw data for **F-H**.

Intriguingly, the R023 scDb also killed sotorasib-treated H2030-Nluc (expressing HLA-A11) and SW1573-Nluc (expressing HLA-A02), as anticipated from the binding profile of R023 Fab to purified soto-p/MHC complexes (Figs. 2B and C and 4G and H; Supplementary Fig. S5C–S5D). These results demonstrate the potential of the HapImmune approach to enable a single antibody to effectively target cancer cells with distinct HLA supertypes.

Development of HapImmune Antibodies Selective to Other Drug-Target Conjugates in Complex with an MHC

To test the general applicability of our HapImmune approach, we also developed antibodies selective to the osimertinib-EGFR conjugate presented on an MHC. Osimertinib covalently binds to endogenous C797 of activated EGFRs, such as EGFR(T790M) (46). NetMHCpan predicted




Figure 5. Binding and cell killing analyses of HapImmune antibody E021 against osimertinib-EGFR peptide conjugate in complex with HLA-A*02. **A**, CDR sequences of clones E001 and E021. Middle, the enrichment profiles of amino acid substitutions deduced from DMS of CDR-L3 and CDR-H3 positions. Data are presented as in Fig. 2A. **B**, Binding analysis of E021 using yeast display. arbit., arbitrary; MFI, median fluorescence intensity. **C**, Effect of free osimertinib on binding of E021 to osim-p791/A02. Binding signals were normalized to that in the absence of osimertinib. The IC_{50} value is the mean \pm SD ($n = 3$, technical replicates). **D**, Cytotoxic effect of the E021 scDb on OCI-AML3 cells pulsed with osim-p791 or p791. Note that the E021 scDb showed potent cytotoxic effect on cells pulsed with the osimertinib-EGFR conjugate but not with the control peptide. **E**, Cytotoxic effects of E021 scDb on osimertinib-treated OCI-AML3 cells, negative control cells that do not possess activating EGFR mutants. Data are from triplicate measurements, and calculated EC_{50} values are shown (mean \pm SD; $n = 3$, technical replicates). BB7.2 is a positive control that binds to HLA-A2 irrespective of the bound peptide. Data shown are representative of ≥ 2 equivalent measurements.

a fragment corresponding to residues 791 to 799 (hereafter p791) to be a strong ligand for HLA-A*02 (Fig. 1C). Using essentially the same methods, we first identified an antibody that specifically recognizes the osim-p791/A02 complex over the p791^{WT}/A02 complex. By using iterative approaches similar to those described above, including DMS to define a sequence landscape of potential binders (Fig. 5A), we improved the affinity and specificity of this antibody and developed clone E021, which showed strong binding to the osim-p791/A02 complex ($K_{D,app} \sim 17 \text{ nmol/L}$) and no binding to the p791/A02 complex (Fig. 5B). Binding was minimally inhibited by free osimertinib, with an IC_{50} value of $\sim 100 \mu\text{mol/L}$ (Fig. 5C).

We then produced E021 in the scDb format. The resultant E021 scDb potently killed OCI-AML3 cells pulsed with the osim-p791 conjugate with an EC_{50} of 0.3 pmol/L (Fig. 5D), but

not cells pulsed with the p791^{WT} peptide (Fig. 5D) or unpulsed cells treated with osimertinib (Fig. 5E). Finally, we tested our approach with yet another inhibitor-target pair, ibrutinib and BTK (47). Taking an equivalent approach, we identified initial antibody hits that bound to the ibru-p476/HLA-A*01 complex but not to p476/HLA-A*01 without inhibitor conjugation (Supplementary Fig. S7). These data provide strong evidence for the general applicability of the HapImmune approach.

DISCUSSION

We have shown that a covalent inhibitor conjugated to a peptide can be presented on HLA molecules and that “TCR-like” antibodies that bind selectively to such an inhibitor-p/MHC complex can be developed. These antibodies, when

formatted as bispecific T-cell engagers, can efficiently and selectively kill inhibitor-resistant cancer cells. Although we did not attempt to directly detect the drug-p/MHC complexes using immunopeptidomics, the efficient, MHC-dependent killing of sotorasib-treated H2122 cells by the R023 scDb provides strong evidence for its presence on the cell surface at sufficient density. Importantly, because HapImmune antibodies bind the drug/peptide/MHC complex, not the hapten itself, binding and T cell-dependent killing occur even in the presence of a large excess of the free drug. These properties suggest that covalent drugs and HapImmune antibodies could be deployed concurrently. Furthermore, we were able to generate antibodies with these properties against drug-peptide conjugates generated with structurally distinct covalent inhibitors in complex with different MHCs, confirming this approach as a novel therapeutic strategy that unifies targeted and immune therapies.

We were successful in developing HapImmune antibodies against all three initial targets comprising chemically diverse drugs conjugated to distinct peptides that are presented on different HLA supertypes. Deep mutational scanning identified a total of 73 single-point mutants of clone R011 targeting soto-p/MHC (Fig. 2A), suggesting that many more antibodies can be developed for this antigen. In parallel to developing HapImmune antibodies, we attempted to generate antibodies selective to other nonconjugated neoantigen peptides corresponding to other KRAS mutations (p_8 peptides harboring G12D, G12V, or G13D) presented on HLA-A*03. Despite using the same antigen designs with the same synthetic antibody library and the same overall library sorting strategy, we failed to identify clones selective to any of these neoantigens over the p_8^{WT} /A03 complex. This stark contrast suggests that the conjugation with bulky drugs creates neoantigens that are more readily targetable by antibodies and potentially TCRs than conventional, unmodified neoantigen peptides.

Like other approaches to target MHC-presented antigens, HLA restriction limits the HapImmune approach to the subset of patients harboring appropriately matched HLA alleles. However, unlike previous attempts to target MHC complexes bearing unmodified peptides (27), it appears that HapImmune antibodies can recognize drug-peptide conjugates presented by multiple HLA supertypes, as exemplified by the R023 clone (Figs. 2 and 4). First, R023 recognizes sotorasib conjugated to two different peptides. Second, it recognizes both of these peptides presented by homologous but distinct HLA molecules, HLA-A*03 and HLA-A*11. Third, and most significantly, it also recognizes sotorasib conjugated to a substantially different peptide presented on a different HLA supertype, A*02. This degree of cross-HLA targeting is greater than that exhibited by recently reported peptide-centric CARs, which recognize a peptide presented by two divergent HLAs (48). These unique properties of HapImmune antibodies mean that a therapeutic like R023 could, in principle, be deployed in 40% to 50% of the U.S. patient population with tumors bearing KRAS(G12C) (49). Remarkably, R023 achieves this level of cross-reactivity while maintaining strong discrimination between sotorasib-p/MHC and free sotorasib (Fig. 2). These results demonstrate another aspect of the impact of inhibitor conjugation in shifting the focus of p/MHC recognition toward the inhibitor in addition to

making neoantigens more targetable. Our ongoing antibody-engineering, structural, and immunopeptidomics efforts promise to elucidate the molecular basis for this intriguing mode of inhibitor-p/MHC recognition and test the feasibility of developing antibodies that potently target sotorasib, adagrasib, and other covalent drug-peptide conjugates displayed on an even broader repertoire of HLA molecules.

Our ability to develop HapImmune antibodies against multiple inhibitor-p/MHC complexes suggests that the same principles might be applied even more generally to target inhibitor-p/MHC complexes formed by existing (and future) covalent inhibitors that target intracellular proteins. If so, then comprehensive analysis of the immunopeptidome of inhibitor-treated cells could substantially accelerate the HapImmune discovery process. As we demonstrated with sotorasib and H2122 cells, a covalent inhibitor need not inhibit the target cell to be accessible to HapImmune antibody-mediated killing, so long as the inhibitor forms the intended covalent complex and the inhibitor-p/MHC is presented on the cell surface at a sufficient density for antibody recognition. Notably, several recent studies of patient samples showed that sotorasib-resistant tumors almost always retain sotorasib-KRAS(G12C) engagement (33). Consequently, HapImmune antibodies might be useful in the setting of primary or acquired resistance. Even if tumors initially respond well, drug-tolerant persisters or small reservoirs of intrinsically resistant cells could be eradicated by first-line sotorasib/HapImmune antibody administration.

In the CodeBreak-200 trial (50), a randomized trial for second-line disease comparing sotorasib with the standard-of-care docetaxel, progression-free survival was improved by 1 month, but there was no impact on overall survival. In addition, 10% of patients had grade 3/4 liver toxicity, forcing six patients to be removed from the study, whereas two patients experienced drug-induced liver injury. However, this toxicity was mitigated by dose reduction, which may have affected overall survival. These limitations of sotorasib might be mitigated by lowering its dose combined with a HapImmune therapeutic.

We also note that the HapImmune concept is not restricted to hapten-peptides generated by covalent inhibitors. Rather, any protein that is selectively and specifically accessible by a drug-like reactive agent and can be processed to a hapten-peptide and presented on MHC can be targeted. For example, the immunogenicity of cancer-specific proteins such as cancer testis antigens (51) might be augmentable by haptization. Moreover, reactive amino acids other than cysteine (e.g., lysine, aspartate) are potentially targetable. In this context, emerging mass spectrometric databases of reactive proteins (52, 53) could identify new targets and lead small molecules.

We used diabodies as an initial platform to evaluate T cell-dependent killing, but the “recognition end” of HapImmune antibodies can be assembled into multiple formats, including other types of T-cell engagers (bispecific, trispecific), NK-cell engagers, antibody-drug conjugates, radio-conjugates, cytokine conjugates, and even CAR-T/NK cells. The optimal “effector arm” could be tumor- or tumor site-dependent. In principle, it might also be possible to engineer TCRs or TCR derivatives (54) specific for drug-peptide/MHC complexes. Identifying the optimal format for killing tumors in mice is

the major focus of current work in our laboratories. Interestingly, preclinical studies suggest that sotorasib efficacy is greater in the presence of a competent immune system and can be further enhanced by immune-checkpoint inhibition (4). It will be of interest to determine whether sotorasib treatment induces T cells bearing HapImmune-like TCRs.

While this article was in preparation, Zhang and colleagues published a related study targeting another covalent G12Ci, ARS1620, presented on HLAs (55). They developed antibodies using an inhibitor-peptide conjugate in the absence of MHC complex as the antigen, whereas we used inhibitor-p/MHC complexes. Consequently, the main antibody analyzed by Zhang and colleagues, P1A4, does not discriminate between inhibitor-p and inhibitor-p/MHC, and it cannot be used to target cell-surface antigen in the presence of the free inhibitor at a therapeutically relevant concentration. By contrast, as shown in Fig. 4, our scDb effectively killed H2122 cells in the presence of 1 $\mu\text{mol/L}$ sotorasib. We also demonstrate that our approach can be generalized to other covalent drug-peptide complexes. These differences suggest that our strategy may be more useful for lead antibody development and have greater potential for therapeutic application.

METHODS

Antigen Preparation

Peptides were synthesized and purified by Genemed Synthesis. Sotorasib, osimertinib, ARS1620, and MRTX849 were purchased from Selleckchem. Covalent conjugation reactions of peptides to sotorasib, osimertinib, ARS1620, or MRTX849 (referred to as soto-, osim-, ARS-, and MRTX-peptides, respectively) were performed in solution as follows: Soto-peptides were prepared by adding 50 μL of 4 mmol/L peptide dissolved in H_2O to 50 μL of 8 mmol/L sotorasib in 20% dimethylformamide (DMF) in H_2O , followed by the addition of 5 μL 2 M Tris-HCl buffer, pH 8, and subsequently incubating the mixture at 25°C overnight in the dark. All reaction mixtures listed below were incubated in the same manner. Osim-peptides were prepared by mixing 50 μL of 4 mmol/L peptide dissolved in H_2O and 50 μL of 8 mmol/L osimertinib in 50% acetonitrile in H_2O , followed by the addition of 5 μL 2 M Tris-HCl buffer, pH 8, and incubation. ARS-peptides were prepared by mixing 50 μL of 4 mmol/L peptide dissolved in H_2O and 50 μL of 8 mmol/L ARS1620 in 50% acetonitrile in H_2O , followed by the addition of 5 μL 2 M Tris-HCl buffer, pH 8, and incubation. MRTX-peptides were prepared by mixing 50 μL of 4 mmol/L peptide dissolved in H_2O and 50 μL of 8 mmol/L MRTX 849 in 100% DMF, followed by the addition of 5 μL 2 M Tris-HCl buffer, pH 8, and subsequent incubation. The efficiency of all reactions was verified by reversed-phase chromatography with a C18 Eclipse column (Agilent) using an acetonitrile gradient in 0.1% trifluoroacetic acid.

Recombinant MHC heavy chains, HLA-A*02, HLA-A*03, and HLA-A*11, and beta-2-microglobulin ($\beta_2\text{m}$) were expressed using pET-based vectors containing synthetic genes, generally following published procedures (40). All HLA constructs contained a C-terminal His₆ tag and Avi-tag (Avidity). HLA proteins were produced as inclusion bodies in *Escherichia coli* BL21(DE3) coexpressing BirA with 50 $\mu\text{mol/L}$ biotin in the culture medium, resulting in their biosynthetic biotinylation. $\beta_2\text{m}$ containing an N-terminal His₆ tag and a TEV protease cleavage site and was expressed as inclusion bodies in *E. coli* BL21(DE3). HLA proteins were solubilized in urea, purified using Ni-affinity chromatography on an Ni-Sepharose column (Cytiva), and stored in 100 mmol/L Tris-HCl buffer, pH 8, containing 8 M urea. $\beta_2\text{m}$ was refolded on an Ni-Sepharose column using 50 mmol/L

Tris-HCl buffer, pH 8, containing 25 mmol/L NaCl and eluted in 50 mmol/L Tris-HCl buffer, pH 8, containing 25 mmol/L NaCl and 0.5 M imidazole. After removing the N-terminal tag with TEV protease, the sample was purified further using a Superdex S75 column (Cytiva) in 10 mmol/L sodium phosphate and 1.8 mmol/L potassium phosphate buffer, pH 7.4, containing 138 mmol/L NaCl (PBS). Biotinylation of HLA samples was confirmed using gel shift assays (56). Peptide-HLA- $\beta_2\text{m}$ complexes were assembled by refolding as follows: Briefly, a refolding mixture consisting of 30 $\mu\text{mol/L}$ peptide and 3 $\mu\text{mol/L}$ $\beta_2\text{m}$ was prepared in PBS. Next, concentrated HLA in 0.1 M Tris-HCl buffer, pH 8, containing 8 M urea and 0.5 M NaCl was quickly injected into the refolding mixture at a final concentration of 3 $\mu\text{mol/L}$, resulting in a final HLA: $\beta_2\text{m}$:peptide ratio of 1:1:10. After incubation at 4°C overnight, the solution was centrifuged at 20,000 $\times g$, and the supernatant was concentrated with an Amicon centrifugal filter unit with a 10 kDa cutoff (Millipore) and further purified using a Superdex75 10/300 GL column (Cytiva) equilibrated in PBS. Sample purity was typically >95%, as verified using SDS-PAGE. Purified p/MHC complexes were concentrated to >2 $\mu\text{mol/L}$ and stored at -80°C until use.

Antibody Development

Sorting of a synthetic human Fab library was performed as described previously (57) with small modifications. Briefly, a phage library was incubated with drug-p/HLA complexes at concentrations of 100 nmol/L (first and second rounds), 50 nmol/L (third round), and 20 nmol/L (fourth round). In the second and later rounds, phage solutions were first reacted with respective p^{WT}/MHC complexes immobilized on the Streptavidin MagneSphere particles (Promega) to eliminate cross-reactive clones. Sorted phage clones were assessed by multiplex bead binding assay (MBBA; ref. 58).

The A3-2 antibody, selective to HLA-A*03 (and 02), and the A11-1 antibody, selective to HLA-A*11, were developed in an equivalent manner except that negative selection was performed using p/MHC samples of the other supertype to enrich for supertype-selective clones (e.g., p/A11 was used for enriching clones selective for p/A03). Their binding profiles were characterized using the phage MBBA assay (Supplementary Fig. S6).

Affinity maturation of R001 was performed using yeast display following published general procedures (59). The Fab genes were reformatted into the scFv format and cloned into the yeast display vector, pGalAga (60). We first constructed libraries in which two adjacent residues in CDR-H3 and CDR-L3 of R001 were mutated to all amino acid combinations except for Cys, Met, Phe, Asn, and Gln, using oligo pools (Twist Bioscience). Target concentrations for sorting were determined based on the apparent K_D (10 \times , 2 \times , <1 \times , and <1 $\times K_{D,APP}$ for the first, second, third, and fourth rounds, respectively), and 100 nmol/L of the nonconjugated p/MHC complexes were used for negative sorting throughout. An IntelliCyt iQue Screener PLUS flow cytometer (Sartorius) and an S3e fluorescence-activated cell sorter (Bio-Rad) were used for analysis and cell sorting. The second library was constructed by introducing amino acid diversity in the CDR-H1 and CDR-H2 positions following a published design (61) in the enriched pools from the first library. The second library was sorted three times using target concentrations described above, which yielded clone R011.

DMS was performed by constructing a third library, in which we diversified each of the CDR-H3 and CDR-L3 residues of clone R011, one amino acid at a time, using the NNK codon, where N is a mixture of A, T, G, and C, and K is a mixture of G and T. The library was sorted using soto-p₈/A03 and soto-p₇/A03 at target concentrations of 50, 10, and 3 nmol/L for the first, second, and third rounds, respectively. Plasmids containing scFv genes were purified from the enriched pool of yeast cells using ZymoPrep Yeast Plasmid Miniprep II (Zymo Research Corporation), and the scFv genes were amplified and sequenced on a MiSeq sequencer (Illumina). Sequencing data

were analyzed using a set of in-house–developed UNIX and Python scripts to deduce the number of reads for each mutation. Finally, a fourth library was constructed using oligo pools (Twist Bioscience), introducing CDR-L3 and CDR-H3 mutations based on the DMS results. After four rounds of sorting using soto-p₈/A03, soto-p₇/A03, soto-p₈/A11, and soto-p₇/A11 as targets, single clones were analyzed.

Affinity maturation of Fab E001 for osim-p₇₉₁/A02 by the use of DMS was carried out in an equivalent manner, using p₇₉₁/A02 for negative sorting.

Fab Expression

Fabs were expressed and purified as reported previously (57). Briefly, genes encoding antibody clones were cloned into a vector that expresses a Fab with the Avi-tag at the C-terminus of the heavy chain. Fabs were produced in *E. coli* strain 55244 (ATCC) and purified using a HiTrap Protein G affinity column (Cytiva). Purity >90% was confirmed using SDS-PAGE.

Expression and Purification of scDBs

A synthetic gene encoding an anti-human CD3ε monoclonal antibody (clone UCHT1) in an scFv format was synthesized (Integrated DNA Technologies). To construct expression vectors encoding scDBs, genes encoding the variable domains of heavy and light chains of the HapImmune antibodies and UCHT1 with a His-tag at the C-terminus were cloned into the mammalian expression vector pBCAG. Expi293F cells (Thermo Fisher) were transiently transfected with expression vectors using the ExpiFectamine 293 Transfection Kit (Thermo Fisher) according to the manufacturer's protocol. Transfected cells were incubated at 37°C with 8% CO₂ for 7 days, and scDBs were purified from supernatants using a HisTrap excel column (Cytiva), followed by size-exclusion chromatography using a Superdex 200 10/300 column (Cytiva). The purity of the scDb proteins was analyzed by SDS-PAGE.

BLI

Binding kinetics of Fabs were assessed using an Octet RED96e instrument (Sartorius). Briefly, biotinylated Fabs at 50 nmol/L in TBS were loaded on streptavidin SA biosensors to a final immobilization level ranging from 0.5 to 0.8 nm, and binding kinetics were measured against p/MHCs at 1, 4, 6, 16, and 64 nmol/L in TBS buffer, pH 7.4, containing 1% BSA, 5 μmol/L biotin, and 0.005% Tween-20, with an association period of 500 seconds and a dissociation period of 800 seconds. Data were analyzed using global fitting of a 1:1 binding model with Octet Data Analysis software, version 12.0.2.59.

Mammalian Cell Culture

Raji, NCI-H2030, and HEK293 cells were purchased from ATCC. NCI-H2122 and OCI-AML3 cells were obtained from Drs. Thales Papagiannakopoulos and Christopher Park, respectively (NYU Grossman School of Medicine). NCI-H358, NCI-H522, NCI-H1650, and SW1573 cells were obtained as described previously (62). HLA types of these cells were obtained from the TRON Cell Line Portal (TCLP) database (63). The cell lines were tested negative for *Mycoplasma* monthly using a PCR-based *Mycoplasma* testing kit (LiLIF). They have not been authenticated since the first acquisition. Raji, NCI-H358, NCI-H2122, NCI-H522, NCI-H1650, SW1573, and NCI-H2030 cells were maintained in RPMI 1640 media (Thermo Fisher) supplemented with 10% fetal bovine serum (FBS, Gemini Bio) and penicillin/streptomycin (Thermo Fisher) at 37°C with 5% CO₂. HEK293 cells were maintained in Dulbecco's Modified Eagle Medium (Thermo Fisher) supplemented with 10% FBS (Gemini Bio) and penicillin/streptomycin (Thermo Fisher) at 37°C with 5% CO₂. OCI-AML3 cells were maintained with Iscove's Modified Dulbecco's Medium with 20% FBS (Gemini Bio) and penicillin/streptomycin (Thermo

Fisher) at 37°C with 5% CO₂. Expi293F cells (Thermo Fisher) were maintained in Expi293 Expression Medium (Thermo Fisher) at 37°C with 8% CO₂. All cell lines were used within 15 passages after thawing frozen stocks.

Peripheral blood mononuclear cells were purchased from STEM-CELL Technologies. T cells were expanded using CTS OpTimizer T-cell Expansion SFM (Thermo Fisher) and following the manufacturer's protocol. T cells were cultured in CTS OpTimizer T-cell Expansion SFM supplemented with L-glutamine (Thermo Fisher) and penicillin/streptomycin, or in RPMI with 10% FBS and penicillin/streptomycin, in the presence of human IL7 and human IL15 (PeproTech), each at 10 ng/mL.

Cell Line Generation

A lentiviral vector containing NanoLuc engineered from *Oplophorus gracilirostris* (Nluc; ref. 45) was kindly provided by Dr. Preet Chaudhary (USC Keck School of Medicine). Nluc lentivirus was produced as described (35). To generate stable cell lines, 1 mL of viral supernatant with 10 μg/mL polybrene was added to 1 × 10⁶ cells in a 6-well plate and cultured for 8 hours. Media were exchanged and 2 days later, cells were selected in 20 μg/mL blasticidin (InvivoGen). After selection, cell lines expressing NanoLuc were maintained in the media described above in the presence of 10 μg/mL blasticidin (InvivoGen).

To generate H2122 lacking *HLAA3*, H2122-Nluc cells (1 × 10⁶) were transfected with 2 μg of the Cas9/single-guide RNA (sgRNA) vector PX458 (Addgene; plasmid 48138) using Lipofectamine 3000 (Thermo Fisher) in 6-well plates. The following oligonucleotides were used for cloning sgRNAs into pX458: *HLAA3* forward, 5'-CAC CGCATCCTGGGATACTCACGACG-3'; *HLAA3* reverse, 5'-aacCGT CGTGAGTATCCAGGATGC-3'. Two days after transfection, GFP⁺ cells were purified by FACS using a FACSAria IIu SORP cell sorter (BD Biosciences), and single cells were seeded into a 96-well plate. Clones were screened for HLA-A*03 expression by flow-cytometric analysis (see below). These N-Luc cell lines were tested monthly for *Mycoplasma* infection.

Analysis of HLA-A*03 Expression

Raji, H2122, and H2122(HLA-A*03KO) cells were stained with PE-conjugated anti-human HLA-A*03 (clone GAP-A3, BD Biosciences) or PE-conjugated mouse IgG2a isotype (clone MOPC-173, BioLegend) at the manufacturer's recommended concentration. After staining, cells were washed with PBS supplemented with 1% BSA and analyzed using a ZE5 Cell Analyzer (Bio-Rad) or IntelliCyt iQue Screener PLUS (Sartorius).

Cell Viability and Killing Assays

To assess their sotorasib sensitivity, we seeded H2122 and H358 cells (5 × 10³ cells per well) in 96-well plates. The next day, media were replaced with fresh media containing serial dilutions of sotorasib. After 72 hours of incubation, cell viability was assessed by the PrestoBlue assay (Thermo Fisher) following the manufacturer's protocol. Fluorescence was detected using a FlexStation 3 multimode microplate reader (Molecular Devices).

The cytotoxic effects of scDBs on Raji and OCI-AML3 cells were measured by following a published protocol (64). Briefly, cells were stained with carboxyfluorescein succinimidyl ester (Thermo Fisher) and then incubated with 10 μmol/L sotorasib-KRAS(G12C) conjugates or 1 μmol/L osimertinib-EGFR conjugate in the presence of 10 μg/mL human β₂m for 4 hours. Cells were incubated with control peptides in the same manner. To test nonspecific cell killing of drug-treated cells, Raji or OCI-AML3 cells were incubated with 1 μmol/L sotorasib or 1 μmol/L osimertinib in the presence of 10 μg/mL human β₂m for 4 hours. Cells were then harvested using centrifugation and washed in media. Cells pulsed with peptides or treated with

drugs were cocultured with human T cells [effector:target (E:T) = 5:1] in the presence of scDBs for 18 to 21 hours. We used E:T ratios of 5:1 and 10:1 because these ratios are commonly used for bispecific T-cell engagers (65, 66). After incubation, cells were harvested and washed with PBS and then stained with Fixable Viability Dye eFluor660 (Thermo Fisher). After washing, cells were analyzed on an IntelliCyt iQue Screener (Sartorius).

To measure death by quantification of NanoLuc release, H2122-Nluc cells were cultured in the presence of various concentrations of sotorasib for 1 week. For cytotoxicity assays, cells were seeded in 96-well, flat-bottom plates and incubated at 37°C for 24 hours in the presence or absence (DMSO only) of sotorasib. After incubation, cells were cocultured with human T cells (E:T = 10:1) and scDBs in the presence of sotorasib or DMSO, 2 µg/mL β₂m, and 10 ng/mL IL7 and IL15 for 24 hours at 37°C. Supernatants from each well, containing NanoLuc released by dead cells, were transferred to a new 96-well plate, and coelenterazine (Cayman Chemical) was added to the wells at a final concentration of 10 µmol/L. Luminescence was measured with a Synergy Neo2 hybrid multimode reader (BioTek). Statistical analyses were performed using Prism 9 (GraphPad software).

Analysis of Sotorasib Conjugation to KRAS (G12C)

H2122 cells (5 × 10⁵ cells per well) were seeded in 6-well plates. The next day, supernatants were replaced with media containing 100 nmol/L sotorasib or DMSO. After 24-hour incubation, whole-cell lysates were generated in RIPA buffer (50 mmol/L Tris-HCl, pH 7.4, 150 mmol/L NaCl, 2 mmol/L EDTA, 1% NP-40, and 0.1% SDS), supplemented with protease inhibitors (40 µg/mL PMSF, 2 µg/mL antipain, 2 µg/mL pepstatin A, 20 µg/mL leupeptin, and 20 µg/mL aprotinin), and phosphatase inhibitors (10 mmol/L NaF, 1 mmol/L Na₃VO₄, 10 mmol/L β-glycerophosphate, and 10 mmol/L sodium pyrophosphate). After clarification of debris by centrifugation, samples were quantified by using the Bradford Protein Assay Kit (Thermo Fisher). Total lysate protein (20 µg) was resolved by SDS-PAGE and transferred onto PVDF membranes (MilliporeSigma). Membranes were incubated with appropriate primary and secondary antibodies labeled with IRDye (680 nm) and visualized using an Odyssey CLx Imaging System (LI-COR). Antibodies used here were monoclonal pan-RAS antibody (1:1,000; clone Ab-3, Millipore), mouse monoclonal ERK2 antibody (1:1,000; clone D2, Santa Cruz Biotechnology), and IRDye 680LT Goat anti-Mouse IgG (H + L; 1:10,000; LI-COR).

Data Availability

Data were generated by the authors and are available upon request from the corresponding authors. Scripts for DMS analysis have been deposited in GitHub (<https://doi.org/10.5281/zenodo.7115018>).

Authors' Disclosures

T. Hattori reports grants from the NCI during the conduct of the study, as well as a patent for WO/2022/183112 pending. L. Maso reports a patent for WO/2022/183112 pending. A. Koide reports grants from the NCI during the conduct of the study, as well as a patent for PCT/US2022/018171 pending. B.G. Neel reports other support from NYU Langone Health, Northern Biologics, and Navire Pharma, personal fees and other support from Lighthorse Therapeutics, Arvinas, Recursion Pharma, GLG Group, and Repare Therapeutics, and grants from the NCI/NIH (R21 CA267362, R01 CA248896, and P30 CA016087) during the conduct of the study; a patent for 63402606 pending; and during the course of performing these experiments, his wife owned personal shares in Amgen and Regeneron. Amgen markets sotorasib (AMG510), one of the targets herein, and Regeneron has a large bispecific antibody program. S. Koide reports grants from the NCI during the conduct of the study; grants from Puretech Health and Argenx BVBA, and grants and personal fees from Black Diamond Therapeutics outside the submitted work;

a patent for PCT/US2022/018171 pending; and is a cofounder of and holds equity in Revalia Bio. No disclosures were reported by the other authors.

Authors' Contributions

T. Hattori: Formal analysis, investigation, visualization, methodology, writing—original draft, writing—review and editing. **L. Maso:** Formal analysis, investigation, visualization, methodology, writing—original draft, writing—review and editing. **K.Y. Araki:** Investigation, methodology, writing—review and editing. **A. Koide:** Formal analysis, supervision, investigation, methodology, writing—review and editing. **J. Hayman:** Investigation. **P. Akkapeddi:** Investigation. **I. Bang:** Formal analysis, methodology. **B.G. Neel:** Conceptualization, supervision, funding acquisition, investigation, writing—review and editing. **S. Koide:** Conceptualization, resources, formal analysis, supervision, funding acquisition, investigation, methodology, writing—original draft, project administration, writing—review and editing.

Acknowledgments

We thank E. Rajek for assistance and the Perlmutter Cancer Center Genome Technology Center (GTC) and Cytometry and Cell Sorting Laboratory (CCSL) for instrumentation and technical assistance. This work was supported by NIH grants R21CA246457 (T. Hattori), R21CA267362 (B.G. Neel and S. Koide), R01CA248896 (B.G. Neel and Kwok-kin Wong), and P30CA016087 (Cancer Center Support Grant, B.G. Neel), which provided pilot funding for the early stages of this work and support for the GTC and CCSL.

The publication costs of this article were defrayed in part by the payment of publication fees. Therefore, and solely to indicate this fact, this article is hereby marked “advertisement” in accordance with 18 USC section 1734.

Note

Supplementary data for this article are available at Cancer Discovery Online (<http://cancerdiscovery.aacrjournals.org/>).

Received September 22, 2022; revised October 10, 2022; accepted October 11, 2022; published first October 17, 2022.

REFERENCES

- Ahronian LG, Corcoran RB. Strategies for monitoring and combating resistance to combination kinase inhibitors for cancer therapy. *Genome Med* 2017;9:37.
- Konieczkowski DJ, Johannessen CM, Garraway LA. A convergence-based framework for cancer drug resistance. *Cancer Cell* 2018;33:801–15.
- Ostrom JM, Peters U, Sos ML, Wells JA, Shokat KM. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. *Nature* 2013;503:548–51.
- Canon J, Rex K, Saiki AY, Mohr C, Cooke K, Bagal D, et al. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. *Nature* 2019;575:217–23.
- Hong DS, Fakhri MG, Strickler JH, Desai J, Durm GA, Shapiro GI, et al. KRAS(G12C) inhibition with sotorasib in advanced solid tumors. *N Engl J Med* 2020;383:1207–17.
- Ryan MB, Corcoran RB. Therapeutic strategies to target RAS-mutant cancers. *Nat Rev Clin Oncol* 2018;15:709–20.
- Hymowitz SG, Malek S. Targeting the MAPK pathway in RAS mutant cancers. *Cold Spring Harb Perspect Med* 2018;8:a031492.
- Manchado E, Weissmueller S, Morris JP, Chen CC, Wullenkord R, Lujambio A, et al. A combinatorial strategy for treating KRAS-mutant lung cancer. *Nature* 2016;534:647–51.
- Sun C, Hobor S, Bertotti A, Zecchin D, Huang S, Galimi F, et al. Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3. *Cell Rep* 2014;7:86–93.

10. Xue JY, Zhao Y, Aronowitz J, Mai TT, Vides A, Qeriqi B, et al. Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition. *Nature* 2020;577:421–5.
11. Sharma SV, Lee DY, Li B, Quinlan MP, Takahashi F, Maheswaran S, et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. *Cell* 2010;141:69–80.
12. Konieczkowski DJ, Johannessen CM, Abudayyeh O, Kim JW, Cooper ZA, Piris A, et al. A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors. *Cancer Discov* 2014;4:816–27.
13. Shaffer SM, Dunagin MC, Torborg SR, Torre EA, Emert B, Krepler C, et al. Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance. *Nature* 2017;546:431–5.
14. Roesch A, Vultur A, Bogeski I, Wang H, Zimmermann KM, Speicher D, et al. Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1B(high) cells. *Cancer Cell* 2013;23:811–25.
15. Rambow F, Rogiers A, Marin-Bejar O, Aibar S, Femel J, Dewaele M, et al. Toward minimal residual disease-directed therapy in melanoma. *Cell* 2018;174:843–55.
16. Ku SY, Rosario S, Wang Y, Mu P, Seshadri M, Goodrich ZW, et al. Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance. *Science* 2017;355:78–83.
17. Yun S, Vincelle ND, Green MR, Wahner Hendrickson AE, Abraham I. Targeting immune checkpoints in unresectable metastatic cutaneous melanoma: a systematic review and meta-analysis of anti-CTLA-4 and anti-PD-1 agents trials. *Cancer Med* 2016;5:1481–91.
18. Seidel JA, Otsuka A, Kabashima K. anti-PD-1 and Anti-CTLA-4 therapies in cancer: mechanisms of action, efficacy, and limitations. *Front Oncol* 2018;8:86.
19. Schachter J, Ribas A, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). *Lancet* 2017;390:1853–62.
20. Turnis ME, Andrews LP, Vignali DA. Inhibitory receptors as targets for cancer immunotherapy. *Eur J Immunol* 2015;45:1892–905.
21. Mahoney KM, Rennert PD, Freeman GJ. Combination cancer immunotherapy and new immunomodulatory targets. *Nat Rev Drug Discov* 2015;14:561–84.
22. Pettitt D, Arshad Z, Smith J, Stanic T, Hollander G, Brindley D. CAR-T cells: a systematic review and mixed methods analysis of the clinical trial landscape. *Mol Ther* 2018;26:342–53.
23. Chow VA, Shadman M, Gopal AK. Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed/refractory diffuse large B-cell lymphoma. *Blood* 2018;132:777–81.
24. June CH, Sadelain M. Chimeric antigen receptor therapy. *N Engl J Med* 2018;379:64–73.
25. Sharma P, Allison JP. The future of immune checkpoint therapy. *Science* 2015;348:56–61.
26. Tran E, Robbins PF, Lu YC, Prickett TD, Gartner JJ, Jia L, et al. T-cell transfer therapy targeting mutant KRAS in cancer. *N Engl J Med* 2016;375:2255–62.
27. Douglass J, Hsiue EH, Mog BJ, Hwang MS, DiNapoli SR, Pearlman AH, et al. Bispecific antibodies targeting mutant RAS neoantigens. *Sci Immunol* 2021;6:eabd5515.
28. Chang AY, Gejman RS, Brea EJ, Oh CY, Mathias MD, Pankov D, et al. Opportunities and challenges for TCR mimic antibodies in cancer therapy. *Expert Opin Biol Ther* 2016;16:979–87.
29. Carter PJ, Lazar GA. Next generation antibody drugs: pursuit of the ‘high-hanging fruit’. *Nat Rev Drug Discov* 2018;17:197–223.
30. Goebeler ME, Bargou RC. T cell-engaging therapies: BiTEs and beyond. *Nat Rev Clin Oncol* 2020;17:418–34.
31. Skoulidis F, Li BT, Dy GK, Price TJ, Falchook GS, Wolf J, et al. Sotorasib for lung cancers with KRAS p.G12C mutation. *N Engl J Med* 2021;384:2371–81.
32. Koga T, Suda K, Fujino T, Ohara S, Hamada A, Nishino M, et al. KRAS secondary mutations that confer acquired resistance to KRAS G12C inhibitors, sotorasib and adagrasib, and overcoming strategies: insights from in vitro experiments. *J Thorac Oncol* 2021;16:1321–32.
33. Awad MM, Liu S, Rybkin II, Arbour KC, Dilly J, Zhu VW, et al. Acquired resistance to KRAS(G12C) inhibition in cancer. *N Engl J Med* 2021;384:2382–93.
34. Tanaka N, Lin JJ, Li C, Ryan MB, Zhang J, Kiedrowski LA, et al. Clinical acquired resistance to KRAS(G12C) inhibition through a novel KRAS switch-II pocket mutation and polyclonal alterations converging on RAS-MAPK reactivation. *Cancer Discov* 2021;11:1913–22.
35. Fedele C, Li S, Teng KW, Foster CJR, Peng D, Ran H, et al. SHP2 inhibition diminishes KRASG12C cycling and promotes tumor microenvironment remodeling. *J Exp Med* 2021;218:e20201414.
36. Teng KW, Tsai ST, Hattori T, Fedele C, Koide A, Yang C, et al. Selective and noncovalent targeting of RAS mutants for inhibition and degradation. *Nat Commun* 2021;12:2656.
37. Lim S, Khoo R, Juang YC, Gopal P, Zhang H, Yeo C, et al. Exquisitely specific anti-KRAS biodegraders inform on the cellular prevalence of nucleotide-loaded states. *ACS Cent Sci* 2021;7:274–91.
38. Wang Q, Douglass J, Hwang MS, Hsiue EH, Mog BJ, Zhang M, et al. Direct detection and quantification of neoantigens. *Cancer Immunol Res* 2019;7:1748–54.
39. Jurtz V, Paul S, Andreatta M, Marcatili P, Peters B, Nielsen M. NetMHCpan-4.0: improved peptide-MHC class I interaction predictions integrating eluted ligand and peptide binding affinity data. *J Immunol* 2017;199:3360–8.
40. Garboczi DN, Hung DT, Wiley DC. HLA-A2-peptide complexes: refolding and crystallization of molecules expressed in *Escherichia coli* and complexed with single antigenic peptides. *Proc Natl Acad Sci U S A* 1992;89:3429–33.
41. Araya CL, Fowler DM. Deep mutational scanning: assessing protein function on a massive scale. *Trends Biotechnol* 2011;29:435–42.
42. Brüsselbach S, Korn T, Völkel T, Müller R, Kontermann RE. Enzyme recruitment and tumor cell killing in vitro by a secreted bispecific single-chain diabody. *Tumor Targeting* 1999;4:115–23.
43. Beverley PC, Callard RE. Distinctive functional characteristics of human “T” lymphocytes defined by E rosetting or a monoclonal anti-T cell antibody. *Eur J Immunol* 1981;11:329–34.
44. Suh WK, Cohen-Doyle MF, Fruh K, Wang K, Peterson PA, Williams DB. Interaction of MHC class I molecules with the transporter associated with antigen processing. *Science* 1994;264:1322–6.
45. Matta H, Gopalakrishnan R, Choi S, Prakash R, Natarajan V, Prins R, et al. Development and characterization of a novel luciferase based cytotoxicity assay. *Sci Rep* 2018;8:199.
46. Cross DA, Ashton SE, Ghiorghiu S, Eberlein C, Nebhan CA, Spitzler PJ, et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. *Cancer Discov* 2014;4:1046–61.
47. Honigberg LA, Smith AM, Sirisawad M, Verner E, Loury D, Chang B, et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. *Proc Natl Acad Sci U S A* 2010;107:13075–80.
48. Yarmarkovich M, Marshall QF, Warrington JM, Premaratne R, Farrel A, Groff D, et al. Cross-HLA targeting of intracellular oncoproteins with peptide-centric CARs. *Nature* 2021;599:477–84.
49. Maier M, Gragert L, Klitz W. High-resolution HLA alleles and haplotypes in the United States population. *Hum Immunol* 2007;68:779–88.
50. Johnson ML, De Langen J, Waterhouse DM, Mazieres J, Dingemans AC, Mountzios G, et al. Sotorasib versus docetaxel for previously treated non-small cell lung cancer with KRAS G12C mutation: CodeBreak200 phase III study. *Ann Oncol* 2022;33:S808–S69.
51. Simpson AJ, Caballero OL, Jungbluth A, Chen YT, Old LJ. Cancer/testis antigens, gametogenesis and cancer. *Nat Rev Cancer* 2005;5:615–25.
52. Niphakis MJ, Cravatt BF. Enzyme inhibitor discovery by activity-based protein profiling. *Annu Rev Biochem* 2014;83:341–77.
53. Abbasov ME, Kavanagh ME, Ichu TA, Lazear MR, Tao Y, Crowley VM, et al. A proteome-wide atlas of lysine-reactive chemistry. *Nat Chem* 2021;13:1081–92.
54. Lowe KL, Cole D, Kenefick R, I OK, Lepore M, Jakobsen BK. Novel TCR-based biologics: mobilising T cells to warm ‘cold’ tumours. *Cancer Treat Rev* 2019;77:35–43.

55. Zhang Z, Rohweder PJ, Ongpipattanakul C, Basu K, Bohn MF, Dugan EJ, et al. A covalent inhibitor of K-Ras(G12C) induces MHC class I presentation of haptenated peptide neoepitopes targetable by immunotherapy. *Cancer Cell* 2022;40:1060–9.
56. Sorenson AE, Askin SP, Schaeffer PM. In-gel detection of biotin–protein conjugates with a green fluorescent streptavidin probe. *Anal Methods* 2015;7:2087–92.
57. Miller KR, Koide A, Leung B, Fitzsimmons J, Yoder B, Yuan H, et al. T cell receptor-like recognition of tumor in vivo by synthetic antibody fragment. *PLoS One* 2012;7:e43746.
58. Hattori T, Koide A, Panchenko T, Romero LA, Teng KW, Corrado AD, et al. Multiplex bead binding assays using off-the-shelf components and common flow cytometers. *J Immunol Methods* 2020;490:112952.
59. Koide A, Koide S. Affinity maturation of single-domain antibodies by yeast surface display. *Methods Mol Biol* 2012;911:431–43.
60. Koide A, Gilbreth RN, Esaki K, Tereshko V, Koide S. High-affinity single-domain binding proteins with a binary-code interface. *Proc Natl Acad Sci U S A* 2007;104:6632–7.
61. Lee CV, Liang WC, Dennis MS, Eigenbrot C, Sidhu SS, Fuh G. High-affinity human antibodies from phage-displayed synthetic Fab libraries with a single framework scaffold. *J Mol Biol* 2004;340:1073–93.
62. Fedele C, Ran H, Diskin B, Wei W, Jen J, Geer MJ, et al. SHP2 inhibition prevents adaptive resistance to MEK inhibitors in multiple cancer models. *Cancer Discov* 2018;8:1237–49.
63. Scholtalbers J, Boegel S, Bukur T, Byl M, Goerges S, Sorn P, et al. TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression. *Genome Med* 2015;7:118.
64. Yamashita M, Kitano S, Aikawa H, Kuchiba A, Hayashi M, Yamamoto N, et al. A novel method for evaluating antibody-dependent cell-mediated cytotoxicity by flowcytometry using cryopreserved human peripheral blood mononuclear cells. *Sci Rep* 2016;6:19772.
65. Aschmoneit N, Steinlein S, Kuhl L, Seifert O, Kontermann RE. A scDb-based trivalent bispecific antibody for T-cell-mediated killing of HER3-expressing cancer cells. *Sci Rep* 2021;11:13880.
66. Dao T, Pankov D, Scott A, Korontsvit T, Zakhaleva V, Xu Y, et al. Therapeutic bispecific T-cell engager antibody targeting the intracellular oncoprotein WT1. *Nat Biotechnol* 2015;33:1079–86.
67. Zhang S, Liu J, Cheng H, Tan S, Qi J, Yan J, et al. Structural basis of cross-allele presentation by HLA-A*0301 and HLA-A*1101 revealed by two HIV-derived peptide complexes. *Mol Immunol* 2011;49:395–401.